Welcome to our dedicated news page for NeuroMetrix (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on NeuroMetrix .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroMetrix 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroMetrix 's position in the market.
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) announced the publication of results from an NIH-funded clinical trial of Quell for chronic chemotherapy-induced peripheral neuropathy (CIPN) in The Journal of Pain. The phase 2 trial showed significant improvement in CIPN-related quality of life, meeting its primary endpoint. Minor adverse events were reported, primarily mild skin irritation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. (NASDAQ: NURO) announced a one-for-eight reverse split of its common stock to increase the per share trading price and comply with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will consolidate every eight shares into one, with no change in nominal par value. No fractional shares will be issued, and shareholders entitled to receive a fractional share will receive a cash payment. Trading on the Nasdaq Capital Market will continue on a split-adjusted basis under the new CUSIP number and symbol 'NURO' on November 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. will present at the Emerging Growth Conference on November 1, 2023. Dr. Shai N. Gozani, Chairman and CEO, will provide an update on business highlights and recent developments, including Quell® neuromodulation technology. The presentation is scheduled for 3:40pm EDT and will last approximately 10 minutes. Registration is required to attend the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
Rhea-AI Summary
NeuroMetrix reports business and financial highlights for Q3 2023. Quell Fibromyalgia shows growth with increased prescriptions and refills. Partnership with National Fibromyalgia Association announced. Clinical trial shows Quell's effectiveness for chemotherapy induced peripheral neuropathy. NASDAQ delisting notice received. Financial results consistent with expectations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.4%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. plans to release its Q3 2023 business and financial highlights on October 26, 2023. The company will host a conference call at 8:00 a.m. Eastern Time on the same day. Participants can register in advance to join the call and access the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. announces sponsorship of the National Fibromyalgia Association, supporting their mission to provide education and support for fibromyalgia patients. Partnership will promote Quell Fibromyalgia and other treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
Rhea-AI Summary
NeuroMetrix to present at Emerging Growth Conference on October 4, 2023, providing business update and Quell® technology evolution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
-
Rhea-AI Summary
NeuroMetrix to present at Emerging Growth Conference on September 6, 2023, highlighting business developments and Quell® technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
NeuroMetrix, Inc.
Nasdaq:NURO
NURO Rankings
NURO Stock Data
9.34M
1.67M
16.03%
5.68%
0.57%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
WALTHAM
About NURO
neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launc